Akebia Therapeutics
AKBA
51 hedge funds and large institutions have $170M invested in Akebia Therapeutics in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 9 closing their positions.
1,373% more call options, than puts
Call options by funds: $1.96M | Put options by funds: $133K
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 50 → 51 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $200M → $170M (-$30M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$10.1M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$2.53M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.35M |
| 4 |
Millennium Management
New York
|
+$1.04M |
| 5 |
AI
Axiom Investors
Greenwich,
Connecticut
|
+$703K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.16M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.04M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.17M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$834K |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$667K |
AKBA Hedge Fund Activity: Q3 2014 in Review
51 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2014, worth a combined $170M — down 15% from $200M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AKBA positions and 9 closed out — a net gain of 1 holder — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $10.1M. The largest seller was Morgan Stanley, cutting an estimated $2.16M.
- 51 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2014, up from 50 in Q2 2014.
- Funds reported $170M of Akebia Therapeutics stock for Q3 2014, down 15% quarter-over-quarter.
- 10 funds opened new Akebia Therapeutics positions in Q3 2014 and 9 closed out, a net change of +1 holder.
- The largest Akebia Therapeutics buyer in Q3 2014 was Eagle Asset Management, an estimated $10.1M added.
- The largest Akebia Therapeutics seller in Q3 2014 was Morgan Stanley, an estimated $2.16M sold.
Based on aggregated 13F filings for Q3 2014.